ARVN Insider Trading
Insider Ownership Percentage: 5.23%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $769,402.28
Arvinas Share Price & Price History
Current Price: $7.59
Price Change: ▼ Price Decrease of -0.45 (-5.60%)
As of 03/28/2025 05:00 PM ET
Arvinas Insider Trading History
Arvinas Institutional Trading History
Data available starting January 2016
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Read More on Arvinas
Volume
3,242,003 shs
Average Volume
991,728 shs
Market Capitalization
$521.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.95
Who are the company insiders with the largest holdings of Arvinas?
Who are the major institutional investors of Arvinas?
Arvinas' top institutional shareholders include:
- Vanguard Group Inc. — 10.28%
- Price T Rowe Associates Inc. MD — 5.97%
- RTW Investments LP — 4.85%
- Bellevue Group AG — 3.48%
- T. Rowe Price Investment Management Inc. — 3.21%
- JPMorgan Chase & Co. — 2.70%
Learn More about top institutional investors of Arvinas stock.
Which major investors are selling Arvinas stock?
Within the last quarter, ARVN stock was sold by these institutional investors:
- JPMorgan Chase & Co.
- Bank of America Corp DE
- Federated Hermes Inc.
- Renaissance Technologies LLC
- American Century Companies Inc.
- Franklin Resources Inc.
- Candriam S.C.A.
- Capula Management Ltd
Within the last year, company insiders that have sold Arvinas company stock include:
- John G Houston (CEO)
- Sean A Cassidy (CFO)
- Ian Taylor (Insider)
- Noah Berkowitz (Insider)
Learn More investors selling Arvinas stock.
Which major investors are buying Arvinas stock?
Within the last quarter, ARVN stock was acquired by institutional investors including:
- T. Rowe Price Investment Management Inc.
- Norges Bank
- Boxer Capital Management LLC
- RTW Investments LP
- ArrowMark Colorado Holdings LLC
- Affinity Asset Advisors LLC
- Schonfeld Strategic Advisors LLC
- Price T Rowe Associates Inc. MD